CytoDyn Inc. reported earnings results for the third quarter and nine months ended February 28, 2022. For the third quarter, the company reported net loss was USD 32.33 million compared to USD 45.21 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.08 a year ago.
For the nine months, revenue was USD 0.266 million. Net loss was USD 100.39 million compared to USD 111.46 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.19 a year ago.